Grenoble (France), 28 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the launch of its initial public offering with a view to listing its shares on the Euronext Growth market (ISIN code: FR0013105954 – ticket: ALNHT).